Visiox Pharma raises $7 million in seed funding

Visiox Pharma is a biopharmaceutical service provider focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases requiring new treatment options, with key products including PDP-716 and SDN-037. Visiox Pharma announced today that it has closed a $7 million seed round from an exclusive group of founding partners and ophthalmology industry leaders.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.